

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED

紛美包裝有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00468)

UPDATE RELATING TO THE INVESTIGATION CHANGE OF INVESTIGATOR AND CONTINUED SUSPENSION OF TRADING

Reference is made to (i) the announcements made by the Company dated 28 February 2025 and 17 April 2025 in relation to, among others, the independent investigation and the appointment of the investigator (the “**Existing Investigator**”); and (ii) the announcement made by the Company dated 2 October 2025 in relation to the key findings of the first-stage investigation (the “**Relevant Announcement**”).

Unless otherwise defined, the capitalised terms shall have the same meanings as defined in the aforementioned announcements.

CHANGE OF INVESTIGATOR

As indicated in the Relevant Announcement, the Special Investigation Committee considers that a second-stage investigation is necessary. The Special Investigation Committee noted that the Existing Investigator was first appointed by the former audit committee of the Company. Having considered the initial scope and the progress of the first-stage investigation, the Special Investigation Committee is of the view that it would be more appropriate to appoint a separate investigator with strong global presence as well as China teams to perform the investigation work at various locations in China (the “**Incoming Investigator**”) for the purpose of the second-stage investigation to further demonstrate the independence and quality of the second-stage investigation. The appointment of the Incoming Investigator will be independent from the directors present at the time when the Restructuring and the related transactions took place. The appointment of the Incoming Investigator takes effect on 18 November 2025.

The Incoming Investigator is specialized in forensics accounting services with one of the leading international accounting firms, which possesses solid experience in supporting independent board committees of Hong Kong listed companies to conduct forensic investigations.

The Special Investigation Committee is finalising the scope of the second stage investigation with the Incoming Investigator and will make further announcement to update the Shareholders and potential investors on the latest progress of the second-stage investigation as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 19 February 2025 and will remain suspended until further notice.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules and the Resumption Guidance to keep its shareholders and potential investors informed of (i) the resumption progress; (ii) the publication of the 2024 Annual Results and the 2025 Interim Results; (iii) the despatch of the 2024 Annual Report and the 2025 Interim Report; (iv) the date of the board meeting for the purposes of considering and approving, among other matters, the 2024 Annual Results and the 2025 Interim Results; and (v) the convention of the annual general meeting of the Company.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Greatview Aseptic Packaging Company Limited
YUAN Xunjun
Chairman and Executive Director

Beijing, the People's Republic of China, 20 November 2025

As at the date of this announcement, the Board comprises two executive directors, namely, Mr. YUAN Xunjun and Mr. LEE Hsien Dar Victor; five non-executive directors, namely, Ms. WANG Ziting, Ms. WANG Yingli, Mr. CHOI Sum Shing Samson, Mr. YUEN Kai Yiu Kelvin and Mr. LI Weijin; and four independent non-executive directors, namely Ms. KOU Chung Yin Mariana, Mr. TANG Poon Tung Denny, Mr. CHOI Wai Hong Clifford and Mr. CHEN Qi.